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he consequences of transporters on central ner-
vous system (CNS) drug development are becoming
increasingly important,due to their influence on clinical
outcome.Membrane transporters provide insight into the
mechanisms of treatment failure,adverse drug reactions,
and individual differences in the management of neuro-
logical and psychiatric disorders.
The presence of uptake and efflux transporters in capil-
lary endothelial cells mediates drug transport from the
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Drug transporters are membrane proteins present in various tissues such as the lymphocytes, intestine, liver, kidney, testis,
placenta, and central nervous system. These transporters play a significant role in drug absorption and distribution to
organic systems, particularly if the organs are protected by blood-organ barriers, such as the blood-brain barrier or the
maternal-fetal barrier. In contrast to neurotransmitters and receptor-coupled transporters or other modes of interneuronal
transmission, drug transporters are not directly involved in specific neuronal functions, but provide global protection to
the central nervous system. The lack of capillary fenestration, the low pinocytic activity, and the tight junctions between
brain capillary and choroid plexus endothelial cells represent further gatekeepers limiting the entrance of endogenous
and exogenous compounds into the central nervous system. Drug transport is a result of the concerted action of efflux and
influx pumps (transporters) located both in the basolateral and apical membranes of brain capillary and choroid plexus
endothelial cells. By regulating efflux and influx of endogenous or exogenous substances, the blood-brain barrier and, to
a lesser extent, the blood-cerebrospinal barrier in the ventricles, represents the main interface between the central ner-
vous system and the blood, ie, the rest of the body. As drug distribution to organs is dependent on the affinity of a sub-
strate for a specific transport system, membrane transporter proteins are increasingly recognized as a key determinant of
drug disposition. Many drug transporters are members of the adenosine triphosphate (ATP)-binding cassette (ABC) trans-
porter superfamily or the solute-linked carrier (SLC) class. The multidrug resistance protein MDR1 (ABCB1), also called P-
glycoprotein, the multidrug resistance-associated proteins MRP1 (ABCC1) and MRP2 (ABCC2), and the breast cancer-resis-
tance protein BCRP (ABCG2) are ATP-dependent efflux transporters expressed in the blood-brain barrier. They belong to
the superfamily of ABC transporters, which export drugs from the intracellular to the extracellular milieu. Members of the
SLC class of solute carriers include, for example, organic ion transporting peptides, organic cation transporters, and organic
ion transporters. They are ATP-independent polypeptides principally expressed at the basolateral membrane of brain cap-
illary and choroid plexus endothelial cells that also mediate drug transport through central nervous system barriers.
© 2006, LLS SAS Dialogues Clin Neurosci. 2006;8:311-321.bloodstream to the organs.For example,these membrane
transporters play an essential role in the digestive tract,
the kidney,and the liver,as well as other organic systems
such as the blood cells,the placenta,and the central ner-
vous system.
1
All cells selectively transport endogenous and exogenous
compounds across their membrane to maintain an intra-
cellular milieu distinct from the outer one;this is achieved
in part by the membrane transporters, which are multi-
specific transport proteins. These transporters display
physiologic functions in terms of transporting endogenous
compounds, eg, hormones, amino acids, bile acids, and
lipids.
2-4 Moreover,membrane transporter mutations may
lead to severe genetic disorders such as cystic fibrosis
(ABCC7),
5 immune deficiency (ABCB2 and ABCB3),
6
intrahepatic cholestasis of pregnancy (ABCB11),
7 persis-
tent hypoglycemia of infancy (ABCC8),
8 X-linked
adrenoleukodystrophy (ABCD1),
9 X-linked ataxia with
sideroblastic anemia (ABCB7),
10 and retinal degeneration
(ABCA4).
11,12
This review focuses on the functional significance of
membrane transporters as drug carriers:their role is con-
stantly increasing in current medical practice,as they rep-
resent a key factor in clinical outcome.
7,13,14
Physiological aspects
The blood-brain barrier (BBB) is a physical barrier,and
maintains a given extracellular environment for neurons
and glial cells in the CNS.The BBB is formed by the con-
nection of closely sealed tight junctions between the cap-
illary endothelial cells, which are not fenestrated and
which display minimal pinocytosis (Figure 1).The capil-
lary endothelial cells form a polarized barrier similar to
that located in the retina or in the renal proximal tubule,
which regulates diffusion of molecules across the BBB,
and limits the entry of xenobiotics via paracellular path-
ways by intercellular tight junctions.
15-17 Not all cerebral
blood vessels are closely sealed with tight junctions:fen-
estrated capillaries are found in the pituitary gland and
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Selected abbreviations and acronyms
ABC adenosine triphosphate-binding cassette
ATP adenosine triphosphate
BBB blood-brain barrier
BCRP breast cancer resistance protein
CNS central nervous system
CSB (blood) cerebrospinal barrier
MDR multidrug resistance
MRP multidrug resistance-associated protein
OAT organic ion transporter
OATP organic anion transporting peptide
OCT organic cation transporter
SLC solute-linked carriers
Figure 1. The blood-brain barrier and drug transporters in the
capillary endothelial cells.
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Figure 2. The cerebrospinal barrier and drug transporters in the
choroid plexus cells.
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Efflux transporterin the cirumventricular organs such as the area postrema,
the lamina terminalis,and the median eminence.
18
The choroid plexus is a highly vascularized epithelial
organ which secretes the cerebrospinal fluid and regu-
lates its composition through active and selective trans-
port processes; it has an active role in the cleansing of
the cerebrospinal fluid of endogenous and exogenous
compounds.
19 The blood cerebrospinal barrier (CSB) is
considered as the second fluid barrier protecting the
central nervous system: it is principally formed by
epithelial cells of the choroid plexus in the ventricles and
the arachnoid membrane. Like the brain capillary
endothelial cells, the choroid plexus epithelial cells are
connected by high-resistance tight junctions, which
closely separate the blood from the cerebrospinal fluid
compartment (Figure 2).
20
Together with the BBB and the CSB, the membrane
transporter systems represent further gatekeepers to the
CNS; these play a critical role in drug disposition.
21
Membrane transporters either enhance or restrict drug
distribution to the target organs. Depending on their
main function,these membrane transporters are divided
into two categories: the efflux (export) and the influx
(uptake) transporters.Influx transport proteins facilitate
and efflux transporters limit drug passage through mem-
brane barriers such as the BBB or the CSB.
22 Several
membrane transporters are found at the apical and baso-
lateral epithelial cell membrane of the brain capillary and
of the choroid plexus endothelial cells (Figure 3).
23
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Drug absorption from the systemic circulation into the
CNS was previously considered a passive process that
depended on drug physicochemical properties such as
molecular size, lipophilicity, and the pKa of a drug.
Although the physicochemical properties of a medica-
tion do affect its absorption and access to target organs,
transporter proteins have a major role in the overall
drug distribution process through their targeted expres-
sion in tissue such as the brain.Until recently,most phar-
macokinetic studies focused only on the role of drug-
metabolizing enzymes as a key determinants of drug
disposition.
24
Phase I enzymatic reactions are mainly represented by
the cytochrome P450 mono-oxygenase system,as well as
by other enzymes such as pseudocholinesterase or alco-
hol dehydrogenase.Phase I enzymatic reactions modify
the chemical structure of the compound itself with either
loss of pharmacological activity or,on the contrary,when
prodrugs are administered,enhanced biological activity
through biotransformation into an active metabolite.
In contrast,Phase II enzymatic reactions are conjugation
reactions that lead to the formation of a covalent linkage
with an endogenously derived compound such as glu-
curonic acid, sulfate, glutathione, or amino acids into
highly polar conjugates excreted into the bile or urine:N-
acetyltransferase 2 or catechol-O-methyltransferase are
examples of enzymes that catalyze phase II reactions.
Drug membrane transporters enable access of com-
pounds to phase I reactions and further elimination after
phase II reactions.
Thus, drug uptake transporters deliver the drug to an
intracellular enzymatic detoxification system,whereas
drug efflux transporters decrease the intracellular load
from the detoxification system.Inhibition of transmem-
brane transporters may lead to a lower substrate uptake
with a poorer intracellular access of the drug to the enzy-
matic systems.
25
This synergy between metabolizing enzymes and drug
transporters accounts for the distribution to brain tissues,
and determines the pharmacokinetic profile of CNS
drugs.
26 Furthermore, substrate similarity is well 
documented between membrane transporters and
cytochrome P450 enzymes.For instance,substrates of the
PGP multidrug resistance protein (MDR1) are usually
substrates of the CYP3A4, digoxin and fexofenadine
excepted.
27
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Figure 3. Examples of drug transporters and localization in cells
forming the CNS barriers. CNS, central nervous system;
SLC, solute-linked carrier.
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SLCO1A2 SLCO1C1 SLCO22A6 SLCO22A8 SLCO22A1
Brain capillary endothelial cell
or choroid plexus endothelial cellCharacterization of drug transporters
Many drug transporters are members of the adenosine
triphosphate (ATP)-binding cassette (ABC) transporter
superfamily or the solute-linked carrier (SLC) class.The
ABC superfamily (ABC transporters) comprises the
main efflux membrane transporters for drug elimination,
and the solute-linked carriers (SLC transporters) are
invlolved with influx and efflux transport function for
drug uptake and export.
28
ABC transporters
The ABC transporters are transmembranous proteins
found in all animal species; they require energy from
ATP hydrolysis to actively remove compounds from the
cell,often against a high concentration gradient.They are
composed of two transmembrane domains that form a
pathway through which the substrates move,and by two
nucleotide-binding domains located at the cytoplasmatic
face of the membrane,providing ATP hydrolysis to allow
substrate translocation across cellular membranes.
29
Members of the ABC superfamily are classified as such
according to consensus sequences including both
domains (Walkers A and Walkers B ATP-binding
motifs),as well as the ABC signature (C motif).
30To date,
49 human ABC family members have been identified,
divided into seven different subfamilies.
The ABC transporter superfamily includes medically
important members such as the multidrug resistance-
associated protein 1 (MRP1) located at the basolateral
plasma membrane domain (abluminal), the multidrug
resistance-associated protein 2 (MRP2),the breast can-
cer resistance protein (BCRP),and MDR1 (also known
as PGP) localized at the apical membrane (luminal).
MDR1 (encoded ABCB1), BCRP (encoded ABCG2),
MRP1 (encoded ABCC1), and MRP2 (encoded
ABCC2) were identified in the BBB at the luminal side
of the capillary endothelial cells, MRP1 excepted
(Figure 3).
The substrates handled by the ABC transporters include
a wide range of endogenous and exogenous compounds
and diverse type of molecules,from organic cations and
anions to larger molecules such as large polypeptides or
therapeutic agents.For instance,MRP1 has preferential
transport of anionic compounds such as sulfate conju-
gates or glutathione,whereas MDR1 shows broader sub-
strate specificity.
31,32
Variation of ABC transporter activity by drug-drug inter-
actions, genetic polymorphisms, and overexpression is
considered as a major cause of treatment failure,
interindividual variability,and adverse drug reactions.
25,33
However,randomized controlled studies on these issues
with antidepressants,antipsychotics,or mood stabilizers
in humans are still lacking.
ABC transporters are considered as the most relevant
determinants of efflux transport and provide multiple
barriers in the brain capillary and choroid plexus
endothelial cells.
34A multidrug resistance feature is asso-
ciated with a poorer clinical outcome in several CNS dis-
orders.
24 Furthermore, several ABC transporters were
directly implicated in drug delivery to brain neoplasms
and in the response to therapeutic agents.
35 For instance,
the expression of the ABC transporters ABCC4 and
ABCC5 was associated with an astrocytic phenotype
with higher chemoresistance of astrocytic tumors com-
pared with oligodendrogliomas.
36 Recently, the ABC
transporters were also found to be associated with phar-
macoresistance to anticonvulsant drugs in patients with
intractable mesial temporal lobe epilepsy.
37
MDR1 activity significantly decreases during aging with,
consecutively,an increased brain exposure to drugs and
toxins in elderly subjects.
38 Furthermore,impaired MDR1
function is reported as a predisposing factor in the devel-
opment of neurodegenerative diseases such as Parkinson's
disease or sporadic Alzheimer's dementia.
39 Pathologic
accumulation of amyloid β in Alzheimer's disease may
result from an impaired MDR1 activity, as amyloid β is
considered as a substrate for MDR1.
13
SLC transporters
The SLC class of solute carriers consists of specific mem-
brane transporters that mediate sodium-independent
transmembrane solute transport: it is divided into 43
human families based upon amino acid homology of at
least 25% between family members.To date,nearly 300
genes have been identified.
40 The Human Genome
Organization (HUGO) Nomenclature Committee
Database provides information about new transporter
families of the SLC gene series (SLC transporters-gene
nomenclature, SLCO).
41 Members of the SCLO super-
family are not only expressed in the BBB and in the
choroid plexus,but also in the small intestine,the liver,the
kidney,the blood-testis barrier,and the placenta.
42,43
The SLCO superfamily of solute carriers includes carriers,
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(OATPs), the organic anion transporter family (OATs,
SLCO22A), and the organic cation transporter family
(OCTs, SLCO22A). The organic cation/carnitine trans-
porter (OCTN,SLCO22A),the monocarboxylate trans-
porter family (MCTs, SLCO16), and the peptide trans-
porter (PEPT, SLCO15A) may represent further
important SLC families,and their function as CNS barriers
is currently under investigation.
44,45 For example,α-hydrox-
ybutyrate (GHB),a therapeutic agent for catalepsy with
narcolepsy,undergoes passive diffusion through the BBB
but also the MCT1 carrier-mediated process, that is sat-
urable and can be inhibited.
46 Proof-of-concept studies are
being conducted to provide better insights into GHB ther-
apy and GHB toxicity by means of transport inhibitors.
47
Several in vitro and in vivo data indicate that OATP1A2,
OATP1C1,and OATP2B1 (members of the SLCO21A
family), and OAT1, OAT2, OCT1, OCT2, and OCT3
(members of the SLCO22A family) are expressed in the
murine and human brain, and mediate drug transport
through the CNS barriers.
2-4,36,41,48,49
The SLCO21A family is referred to as the OATP family:
these transporters consist of 12 transmembrane domain
proteins,whose substrates are anionic amphipathic high-
molecular-weight molecules that bind to albumin.
40The
transport mechanism is based upon anion exchange cou-
pled to cellular uptake of organic compounds with the
efflux of bicarbonate,glutathione,and conjugates.
The SLC22A transporters include OCTs including
OCTN,and OATs that also consist of 12 transmembrane
domain proteins,but with different substrate specificity.
Indeed,OATPs not only mediate uptake of anionic,but
also neutral and cationic,compounds.OCT members are
mainly unidirectional porters,whereas OAT members act
as anion exchangers.The organic anion transporting pro-
teins (OATPs),OATs,and the OCTs represent the major
uptake transport systems that mediate organic com-
pound transport activities at the apical and the basolat-
eral plasma membrane domains.
Drug transporter polymorphisms
The expression of transport proteins localized in the
membranes of various organs are significant determi-
nants of the pharmacokinetics of therapeutic agent
including at the level of the CSB and the BBB.
33,50-53
There is genetic polymorphism of drug transporters in
the structure of genes and in the number of alleles.The
MDR1 gene has been particularly well investigated and
several MDR1 polymorphisms have been found:many
of them determine membrane transporters expression in
the BBB and in the CNS with variable drug transport
activity.
26,54,55 Such medically relevant polymorphisms are
called nonsynonymous polymorphisms,as they directly
condition the drug transporter function with potentially
variable clinical outcomes.
The functional significance of different MDR1 expression
for drug disposition was mainly studied with MDR1 knock-
out mice. For instance, MDR1 knockout mice are 50- to
100-fold more sensitive to the neurotoxic pesticide iver-
mectine,and the accumulation of this drug in the CNS was
80- to 100-fold greater when compared with control mice.
56
In humans,several mutations resulting in several MDR1
single nucleotide polymorphisms (SNPs) have been iden-
tified,but only those at positions 2677 and 3435 seem to
be associated with changes in PGP expression and func-
tion.
25,57,58 In contrast to the P450 drug-metabolizing
enzymes such as CYP2C9,CYP2C19,and CYP2D6,for
which loss of function mutations or gene amplification
manifests as distinct phenotypes in the population (eg,
poor,intermediate,extensive,or ultrarapid metabolizers),
the impact of MDR1 polymorphisms on pharmacokinet-
ics is moderate: no definite MDR1 phenotype is recog-
nized in humans.
59There is no complete loss of transport
function when polymorphisms are present:the genotype-
related differences in the MDR1 expression between,eg,
the 3435 genotype, remains moderate with substantial
overlap.
59 However,the difference between clinical out-
comes may be in some conditions very impressive:patients
with drug-resistant epilepsy were much more likely to
have the CC genotype at ABCB1 3435 than the TT geno-
type (odds ratio:2.66).
60 Furthermore,ABC transporter
polymorphisms are not only associated with resistance to
treatment or failure,for example,for anticonvulsants,cyto-
statics,or antibiotics,but they also determine the incidence
of adverse drug events.
50,53,57,60-63 Some examples of clinical
effects and potential implications associated with human
drug transporter polymorphisms are listed in Table I.
Interestingly,the clinical impact of single nucleotide poly-
morphisms on genetic variability of expression and func-
tion of the multidrug resistance-associated proteins
(MRPs,ABCC transporter) is to date rather limited as
compared with eg,MDR1.
73 Outside the CNS,multiple
but rare familial mutations in, eg, the ABCC2 gene
(MRP2) are responsible for the recessive inherited
Dubin-Johnson syndrome:although hepatic function is
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risk of drug-induced liver toxicity.
74
Although SLCO transporters are genetically extensively
characterized,relevant clinical data about the impact of
polymorphisms are still limited. Genetic variants of
uptake transporters have predominantly been investi-
gated for OATPs,but a large number of single nucleotide
polymorphisms in the OCT1 (SLCO22A1) and OCT2
(SLCO22A2) gene were also found,altering the trans-
port function in vitro.
25,75As OATP1A2 is predominantly
localized in the capillary endothelial cells of the brain,
genetic variability and polymorphisms of this drug
uptake carrier may represent a future pathway for CNS
drugs as it is a determinant of brain toxicity.
23
Drug transporter interactions
Membrane transporters can undergo inhibition or induc-
tion, which respectively slow down or accelerate their
transporter activity.
76-78
In 1951,indirect clinical evidence already suggested the
role of specific transport systems at the level of renal cell
membranes
79:coadministration of probenecid with peni-
cillin resulted in decreased renal clearance, prolonged
half-life,and elevated plasma level of penicillin,enabling
a substantial reduction in antibiotic dose.The mechanism
of this interaction was found several years later: the
active penicillin secretion was reduced by OAT inhibi-
tion in the basolateral membrane of renal proximal
tubule.
80 Similarly,coadministration of probenecid with
HIV antiviral drugs or with antihypertensive drugs such
as the angiotensin-converting enzyme inhibitors also
causes a reduction in renal clearance,a prolonged half-
life,and elevated plasma levels.
81 In humans,digoxin is a
high-affinity substrate for MDR1,and most interacting
drugs are either inductors,or,more frequently,inhibitors,
of MDR1.
82 Significant MDR1 inhibition, by adminis-
trating atorvastatin, clarithromycin, or verapamil as
MDR1 inhibitors, was associated with a significant
increase in the serum digoxin concentration, ie, more
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Table I. Examples of genetic polymorphisms in human drug transporters. ABC, adenosine triphosphate-binding cassette; MDR, multi-drug resis-
tance; BCRP, breast cancer resistance protein; SLC, solute-linked carriers; OATP, organic anion transporting peptide; OAT, organic ion trans-
porter; OCT, organic cation transporter; CNS, central nervous system.
Symbol Transporter Polymorphism Associated clinical effect
ABCB1 MDR1 3435 C>T 3435 C epilepsy drug-resistance
60
3435 TT fewer viral resistance in efavirenz patients,
64 higher digoxin level,
65
and nortriptyline-induced postural hypotension
66
ABCB1 MDR1 1236 C>T 1236 decreased survival in acute myeloid leukaemia patients
67
ABCB1 MDR1 2677 G>T/A 2677 T tacrolimus-induced neurotoxicity
68
ABCG2 BCRP C421A Increased plasma concentration of diflomotecan
69
SCL21A3 OATP1A2 38T>C, 382A>T CNS penetration and toxicity of various drugs and substrates
52
404A>T, 516A>C
559 G>A, 2003 C>G
SLC22A6 OAT1 1361G>A, 877C>T Possible altered renal uptake of cidofovir and adefovir and drug-induced nephrotoxicity
70
677T>C, 767C>T
SLC22A1 OCT1 181C>T, 1201G>A Decreased substrate uptake in vitro
71
SLC22A2 OCT2 1198C>T, 495G>A Decreased substrate uptake in vitro
72
Table II. Examples of drug-drug interactions involving drug transporters. MDR, multidrug resistance; CNS, central nervous system; OCT, organic
cation transporter; OATP, organic anion transporting peptide; OAT, organic ion transporter.
Drug - substrate Inhibitor / inducer Interaction Effect
Loperamide Quinidine MDR1 inhibition Increased CNS penetration of loperamide
87
Digoxin Paroxetine MDR1 inhibition Increased CNS penetration of digoxin
75
Cyclosporine St John's wort MDR1 induction Decreased plasma level of cyclosporine
91
Desipramine Ritonavir OCT1 inhibition Decreased hepatic uptake with poorer access to CYP3A4
92
Fexofenadine Fruit juices OATP inhibition Decreased oral bioavailability
93
Penicillin Probenecid OAT inhibition Prolonged penicillin half-life by reduced renal clearance
81than twice the upper therapeutic limit.
76,78,83,84 Another
striking and clinically relevant effect of the PGP-associ-
ated interactions was demonstrated by giving healthy
volunteers loperamide, an opiate that is not absorbed
from the gut, simultaneously with quinidine, a potent
MDR1 inhibitor:coadministration of this antidiarrheal
agent with quinidine resulted in central opioid effect such
as respiratory depression and euphoria,
85,86 confirming in
vivo a major MDR1 inhibition in the intestinal and in the
BBB gatekeeper function.
52,87
Recently,a population pharmacokinetic analysis of drug-
drug interactions between risperidone,bupropion,and
sertraline in rodents suggested that sertraline produces
significant inhibitory effects on MDR1 transport at the
BBB, increasing the brain entry of risperidone and its
metabolite 9-OH-risperidone.
88The order of magnitude
was high,and could be clinically significant for humans:
sertraline did not change the plasma concentration of
risperidone and of its metabolite,but increased the brain
area under the plasma concentration curve of risperidone
and 9-hydroxy-risperidone 1.5-fold (P<0.05) and 5-fold
(P<0.01),respectively.
88
Interestingly,another study with rodents showed that the
MDR1 localized in the BBB is more resistant to inhibi-
tion than in other tissues.
51 In vivo studies in humans are
needed to assess the clinical relevance of such differen-
tial sensitivity to inhibition.
In vitro techniques for the assessment of drug-drug
interactions involving membrane transporters are cur-
rently under development.
89 Inhibition on the MDR1
was investigated in vitro with recent antidepressants,
displaying different interaction potentials: whereas
paroxetine is regarded as a strong PGP inhibitor,citalo-
pram and venlafaxine are considered as antidepressants
with low interaction potential with membrane trans-
porters.
77,90A case report confirmed the ability of parox-
etine to inhibit the PGP in the BBB and in the kidney,
causing digitalis intoxication with delirium, visual hal-
lucinations,and disorientation.
78 However,specific data
from in vivo studies,substrate specificity,and inhibition
or induction potential of psychiatric and neurological
medication are still lacking. Examples related to drug-
drug interaction at the membrane transporter level are
illustrated in Table II.
Discussion
In vitro and in vivo studies show that drug carriers are
expressed in the BBB and in the CSB.They represent
major determinants of toxicity and clinical outcome
related to drug response.Understanding the functional
significance of membrane transporters in the BBB and
in the CSB provides further opportunities to improve
drug delivery to the CNS.
We propose that the role of transporter proteins should
be studied at an early stage of CNS drug development,
as there are in vitro methods such as cell cultures to
achieve this purpose.Knockout animals are valuable in
vivo models, but in vivo methods in humans are few.
Direct in vivo determinations of drug concentration and
effective transporter function into the brain remain par-
ticularly challenging,as invasive techniques are necessary.
Neuroimaging techniques should be helpful,since mole-
cules can be measured by positron emission tomography
(PET) or by magnetic resonance imaging spectrometry.For
example,the latter can be used to assess the pharmacoki-
netics of some fluoride-containing molecules in the brain.
Although several members of the membrane transporters
present in the BBB have been characterized in detail,
numerous questions remain open.Firstly,the determina-
tion of detailed tissue expressions and in vivo studies of
carriers with better specificity are required to target more
efficiently therapeutic agents into the CNS and into other
organs.Secondly,in order to enhance the potential clinical
implications of drug transporter polymorphisms and inter-
actions, the development of specific inductors and
inhibitors may represent promising strategies.
Thirdly,future delivery procedures include the use of pro-
drugs,drug-targeting vector conjugates,or liposomes tagged
with targeting vectors to elude physiological barriers.
Drug transporter protein studies provide insight into the
mechanisms of resistance, treatment failure, and
interindividual response to neurological and psychiatric
medication.Membrane transporter proteins are not only
CNS gatekeepers,but represent determinant partners in
CNS drug development strategies.Exploring the func-
tional significance of membrane transporters in drug
delivery to the CNS is essential for the treatment of neu-
rological and psychiatric disorders. ❏
Drug transporters,blood-brain barrier,and the CNS - Girardin Dialogues in Clinical Neuroscience - Vol 8 . No.3 . 2006
317Pharmacological aspects
318
Proteínas transportadoras de membrana: un desafío para el desarrollo de fármacos para el
sistema nervioso central
Los transportadores de fármacos son proteínas de membrana presentes en varios tejidos como linfocitos, intes-
tino, hígado, riñón, testículos, placenta y el sistema nervioso central. Estos transportadores juegan un papel
significativo en la absorción de fármacos y en la distribución a los sistemas del organismo, especialmente si
los órganos están protegidos por barreras sangre-órgano, como la barrera hémato-encefálica o la barrera
materno-fetal. En contraste con los neurotransmisores y los transportadores acoplados a receptores u otros
modos de transmisión interneuronal, los transportadores de fármacos no están directamente involucrados en
funciones neuronales específicas, pero proveen una protección global al sistema nervioso central. La falta de
capilarización, la baja actividad de los pinocitos, y las uniones estrechas entre los capilares cerebrales y las célu-
las endoteliales de los plexos coroídeos representan más barreras que limitan la entrada de compuestos endó-
genos y exógenos al sistema nervioso central. El transporte de fármacos es el resultado de una acción con-
certada de bombas de entrada y salida (transportadores) ubicadas en las membranas basolaterales y apicales
de los capilares cerebrales y de las células endoteliales de los plexos coroídeos. En la regulación de la entrada
y salida de las sustancias endógenas o exógenas, la barrera hémato-encefálica, y en menor medida la barrera
hémato-cerebroespinal en los ventrículos, representan el principal punto de contacto entre el sistema ner-
vioso central y la sangre, es decir, el resto del organismo. Como la distribución de los fármacos a los órganos
depende de la afinidad de un sustrato por un sistema de transporte específico, las proteínas transportadoras
de membrana están siendo cada vez más reconocidas como un factor determinante en la disponibilidad de
los fármacos. Muchos transportadores de fármacos son miembros de la superfamilia del transportador (ABC)
unido a adenosín trifosfato (ATP) o de la clase de transportadores unidos a soluto (SLC). La proteína de resis-
tencia a multifármacos MDR1 (ABCB1), también llamada P-glicoproteína, las proteínas asociadas a resisten-
cia a multifármacos MRP1 (ABCC1) y MRP2 (ABCC2), y la proteína de resistencia al cáncer de mama BCRP
(ABCG2) son transportadores de salida dependientes de ATP que se expresan en la barrera hémato-encefá-
lica. Ellos pertenecen a la superfamilia de transportadores ABC, los cuales llevan fármacos desde el medio
intracelular al extracelular. Los miembros de la clase SLC de los transportadores de soluto incluyen, por ejem-
plo, péptidos transportadores de iones orgánicos, transportadores de cationes orgánicos y transportadores
de iones orgánicos. Ellos son polipéptidos independientes de ATP que se expresan principalmente en la mem-
brana basolateral de los capilares cerebrales y las células endoteliales de los plexos coroídeos que también
median el transporte de fármacos a través de las barreras del sistema nervioso central.  
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Protéines de transport membranaires : un défi pour le développement des médicaments du
SNC
Les transporteurs de médicaments (drug transporters) sont des protéines situés dans les membranes cel-
lulaires de différents tissus comme les lymphocytes, l’intestin, le foie, les reins, les testicules, le placenta ou
le SNC (système nerveux central). Ces transporteurs jouent un rôle primordial dans l’absorption et la dis-
tribution des médicaments dans les organes cibles, surtout s'ils sont protégés par des structures comme la
barrière hématoencéphalique (BHE) ou la barrière maternofœtale. Contrairement aux transporteurs liés à
des récepteurs ou à la transmission interneuronale, ces transporteurs membranaires ne sont pas directe-
ment impliqués dans une fonction neuronale spécifique mais assurent une protection globale du système
nerveux central. Le transport de médicaments est la résultante des mécanismes d’efflux (sortie) et d’influx
(entrée) situés au niveau de la membrane apicale et basolatérale des cellules endothéliales des capillaires
cérébraux et du plexus choroïdien. En régulant l’efflux et l’influx des substances endogènes ou exogènes,
la BHE et la barrière hémato-cérébro-spinale représentent les principales interfaces entre le système ner-
veux central et le sang. La distribution d’un médicament vers les organes cibles est dépendante de son affi-
nité pour un système de transport spécifique : les transporteurs membranaires sont ainsi reconnus comme
un élément clé dans la disposition des médicaments au niveau du système nerveux central. Plusieurs trans-
porteurs membranaires font partie de la superfamille ABC (ATP-Binding Cassette) ou SLC (Solute Carriers).
La Multi-Drug Resistance protein MDR1 (ABCB1) nommée aussi P-glycoprotéine, les Multidrug Resistance-
associated Proteins MRP1 (ABCC1) et MRP2 (ABCC2), ainsi que la Breast Cancer Resistance Protein BCRP
(ABCG2) sont des transporteurs d'efflux ATP-dépendants présents au niveau de la BHE et qui appartien-
nent à la superfamille des transporteurs ABC. Les OATPs (Organic Anion Transporter Proteins), OCTs (Organic
Cation Transporters) et OATs (Organic Anion Transporters) font partie des transporteurs ATP-indépendants
de type SLC constitués de polypeptides (solute carriers). Les conséquences cliniques des transporteurs mem-
branaires semblent jouer un rôle de plus en plus important dans le développement de nouveaux médica-
ments, particulièrement en neurologie et en psychiatrie. Les différents mécanismes qui régulent le trans-
port de molécules à travers les membranes cellulaires et les barrières organiques sont des éléments clés
pour expliquer les mécanismes d’échec ou de résistance au traitement, ainsi que certains effets indésirables
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